A propensity score-matched analysis of neoadjuvant chemoimmunotherapy versus surgery alone for locally advanced esophageal squamous cell carcinoma

被引：5

作者：

Wang, Kexi ^{[1
]}

Liang, Yicheng ^{[1
]}

Huang, Jing ^{[1
]}

Xie, Xuan ^{[1
]}

Wu, Duoguang ^{[1
]}

Chen, Baishen ^{[1
]}

Wang, Kefeng ^{[1
]}

Shen, Zhuojian ^{[1
]}

Li, Yuquan ^{[1
]}

Wang, Wenjian ^{[1
]}

Hu, Xueting ^{[1
]}

Wang, Minghui ^{[1
,2
]}

机构：

[1] Sun Yat Sen Univ, Sun Yat sen Mem Hosp, Dept Thorac Surg, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou, Peoples R China

[2] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Thorac Surg, 107 Yanjiangxi Rd, Guangzhou 510120, Peoples R China

来源：

JOURNAL OF SURGICAL ONCOLOGY | 2023年 / 128卷 / 02期

基金：

中国国家自然科学基金;

关键词：

esophageal squamous cell carcinoma; neoadjuvant immunotherapy combined with chemotherapy; postoperative complications; propensity score matching; surgery alone; CHEMORADIOTHERAPY PLUS SURGERY; CHEMOTHERAPY; CANCER; SAFETY; IMMUNOTHERAPY; CAMRELIZUMAB; MULTICENTER; NIVOLUMAB; EFFICACY; THERAPY;

D O I：

10.1002/jso.27277

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundThe aim of this study was to evaluate the safety, efficacy, and oncologic outcomes of neoadjuvant immunotherapy combined with chemotherapy (NICT) group and surgery alone group in the treatment of patients with locally advanced esophageal squamous cell carcinoma (ESCC). MethodsA series of 232 consecutive patients who underwent surgery with or without NICT from June 2019 to August 2022 were evaluated. We performed propensity score matching between the NICT and surgery alone groups on the basis of estimated propensity scores for each patient. ResultsAfter propensity score matching, data of 137 patients with clinical stages II-IV ESCC, including 85 receiving surgery alone and 52 receiving NICT, were analyzed. Compared with the surgery alone group (301.7 +/- 94.4 min), the operation time was significantly longer in the NICT group (333.4 +/- 79.7 min). However, there was no significant difference between the two groups in the postoperative complications, intraoperative blood loss, thoracic fluid volume, chest tube duration, lengths of intensive care unit stay and postoperative hospitalization. Additionally, 90-day mortality rate and 30-day readmission were similar in both groups. ConclusionsOverall, NICT followed by esophagectomy appears to be safe and feasible for locally advanced ESCC. However, further multicenter prospective clinical trials are needed to validate our results.

引用

页码：207 / 217

页数：11

共 40 条

[1] Esophageal and Esophagogastric Junction Cancers, Version 2.2019 [J].

Ajani, Jaffer A. ;

D'Amico, Thomas A. ;

Bentrem, David J. ;

Chao, Joseph ;

Corvera, Carlos ;

Das, Prajnan ;

Denlinger, Crystal S. ;

Enzinger, Peter C. ;

Fanta, Paul ;

Farjah, Farhood ;

Gerdes, Hans ;

Gibson, Michael ;

Glasgow, Robert E. ;

Hayman, James A. ;

Hochwald, Steven ;

Hofstetter, Wayne L. ;

Ilson, David H. ;

Jaroszewski, Dawn ;

Johung, Kimberly L. ;

Keswani, Rajesh N. ;

Kleinberg, Lawrence R. ;

Leong, Stephen ;

Ly, Quan P. ;

Matkowskyj, Kristina A. ;

McNamara, Michael ;

Mulcahy, Mary F. ;

Paluri, Ravi K. ;

Park, Haeseong ;

Perry, Kyle A. ;

Pimiento, Jose ;

Poultsides, George A. ;

Roses, Robert ;

Strong, Vivian E. ;

Wiesner, Georgia ;

Willett, Christopher G. ;

Wright, Cameron D. ;

McMillian, Nicole R. ;

Pluchino, Lenora A. .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (07) :855-883

[2] Esophageal Cancer [J].

Alsop, Benjamin R. ;

Sharma, Prateek .

GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2016, 45 (03) :399-+

[3] A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907) [J].

Ando, Nobutoshi ;

Kato, Hoichi ;

Igaki, Hiroyasu ;

Shinoda, Masayuki ;

Ozawa, Soji ;

Shimizu, Hideaki ;

Nakamura, Tsutomu ;

Yabusaki, Hiroshi ;

Aoyama, Norio ;

Kurita, Akira ;

Ikeda, Kenichiro ;

Kanda, Tatsuo ;

Tsujinaka, Toshimasa ;

Nakamura, Kenichi ;

Fukuda, Haruhiko .

ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (01) :68-74

[4] Safety and Feasibility of Lung Resection After Immunotherapy for Metastatic or Unresectable Tumors [J].

Bott, Matthew J. ;

Cools-Lartigue, Jonathan ;

Tan, Kay See ;

Dycoco, Joseph ;

Bains, Manjit S. ;

Downey, Robert J. ;

Huang, James ;

Isbell, James M. ;

Molena, Daniela ;

Park, Bernard J. ;

Rusch, Valerie W. ;

Sihag, Smita ;

Jones, David R. ;

Adusumilli, Prasad S. .

ANNALS OF THORACIC SURGERY, 2018, 106 (01) :178-183

[5] Initial Experience With Lung Cancer Resection After Treatment With T-Cell Checkpoint Inhibitors [J].

Chaft, Jamie E. ;

Hellmann, Matthew D. ;

Velez, Moises J. ;

Travis, William D. ;

Rusch, Valerie W. .

ANNALS OF THORACIC SURGERY, 2017, 104 (03) :E217-E218

[6] Cancer Statistics in China, 2015 [J].

Chen, Wanqing ;

Zheng, Rongshou ;

Baade, Peter D. ;

Zhang, Siwei ;

Zeng, Hongmei ;

Bray, Freddie ;

Jemal, Ahmedin ;

Yu, Xue Qin ;

He, Jie .

CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (02) :115-132

[7] Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer [J].

Cunningham, David ;

Allum, William H. ;

Stenning, Sally P. ;

Thompson, Jeremy N. ;

Van de Velde, Cornelis J. H. ;

Nicolson, Marianne ;

Scarffe, J. Howard ;

Lofts, Fiona J. ;

Falk, Stephen J. ;

Iveson, Timothy J. ;

Smith, David B. ;

Langley, Ruth E. ;

Verma, Monica ;

Weeden, Simon ;

Chua, Yu Jo .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (01) :11-20

[8] Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma [J].

Doki, Y. ;

Ajani, J. A. ;

Kato, K. ;

Xu, J. ;

Wyrwicz, L. ;

Motoyama, S. ;

Ogata, T. ;

Kawakami, H. ;

Hsu, C. -H. ;

Adenis, A. ;

El Hajbi, F. ;

Di Bartolomeo, M. ;

Braghiroli, M. I. ;

Holtved, E. ;

Ostoich, S. A. ;

Kim, H. R. ;

Ueno, M. ;

Mansoor, W. ;

Yang, W. -C. ;

Liu, T. ;

Bridgewater, J. ;

Makino, T. ;

Xynos, I. ;

Liu, X. ;

Lei, M. ;

Kondo, K. ;

Patel, A. ;

Gricar, J. ;

Chau, I. ;

Kitagawa, Y. .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (05) :449-462

[9] Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial [J].

Eyck, Ben M. ;

van Lanschot, J. Jan B. ;

Hulshof, Maarten C. C. M. ;

van der Wilk, Berend J. ;

Shapiro, Joel ;

van Hagen, Pieter ;

Henegouwen, Mark I. van Berge ;

Wijnhoven, Bas P. L. ;

van Laarhoven, Hanneke W. M. ;

Nieuwenhuijzen, Grard A. P. ;

Hospers, Geke A. P. ;

Bonenkamp, Johannes J. ;

Cuesta, Miguel A. ;

Blaisse, Reinoud J. B. ;

Busch, Olivier R. ;

Creemers, Geert-Jan M. ;

Punt, Cornelis J. A. ;

Plukker, John Th M. ;

Verheul, Henk M. W. ;

Bilgen, Ernst J. Spillenaar ;

van der Sangen, Maurice J. C. ;

Rozema, Tom ;

Ten Kate, Fiebo J. W. ;

Beukema, Jannet C. ;

Piet, Anna H. M. ;

van Rij, Caroline M. ;

Reinders, Janny G. ;

Tilanus, Hugo W. ;

Steyerberg, Ewout W. ;

van der Gaast, Ate .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (18) :1995-+

[10] Safety and Feasibility of Esophagectomy Following Neoadjuvant Immunotherapy Combined with Chemotherapy for Esophageal Squamous Cell Carcinoma [J].

Gu, Yi-Min ;

Shang, Qi-Xin ;

Zhang, Han-Lu ;

Yang, Yu-Shang ;

Wang, Wen-Ping ;

Yuan, Yong ;

Hu, Yang ;

Che, Guo-Wei ;

Chen, Long-Qi .

FRONTIERS IN SURGERY, 2022, 9

← 1 2 3 4 →